DBV Technologies (DBVT) Stock Price

DBV Technologies Price

NYSE·CLOSED
9.77
​
Market closed

Revenue has compounded at 20.5% per year over the past 16 years to 2.57 M USD. DBV Technologies's net margin stands at -4,428.2%, down from -1,415.0% several years earlier.

DBV Technologies stock price

Access this data via the Eulerpool API

DBV Technologies business model & stock analysis

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Frequently asked questions about DBV Technologies

8 analysts currently rate the DBV Technologies stock: 6 recommend buying, 1 holding and 1 selling. For 2026, analysts expect DBV Technologies to generate revenue of 3.58 M USD and earnings per share of -0.70 USD.

Converted at the current exchange rate, the DBV Technologies share trades at 8.72 EUR (9.77 USD).

The expected revenue of DBV Technologies is 3.58 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of DBV Technologies is -53.35 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of DBV Technologies is currently -14.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the DBV Technologies stock.

The price-to-sales ratio (P/S) of DBV Technologies is currently 209.36. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the DBV Technologies stock.

The Eulerpool Quality Score for DBV Technologies is 2/10.

The ISIN of DBV Technologies is US23306J1016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of DBV Technologies is A12EBR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of DBV Technologies is DBVT. The ticker symbol is used to trade DBV Technologies shares on the stock exchange.

Fair ValueTerminal
9.09 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Oct 22, 2014
ISIN
US23306J1016
Cusip
23306J101
Market capitalization
578.25 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-14.03
P/Ee 2027
-26.06
P/Ee 2028
68.99
P/Ee 2029
37.22
P/Ee 2030
14.53
P/Se
209.36
EV/EBIT
—
P/B Ratio
3.43
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-79.41 %
Last updated Oct 8, 2026, 7:45 PM

DBV Technologies Peer Group